DE68919361D1 - Therapeutische zusammensetzungen für die behandlung von myocard-infarkten. - Google Patents

Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.

Info

Publication number
DE68919361D1
DE68919361D1 DE68919361T DE68919361T DE68919361D1 DE 68919361 D1 DE68919361 D1 DE 68919361D1 DE 68919361 T DE68919361 T DE 68919361T DE 68919361 T DE68919361 T DE 68919361T DE 68919361 D1 DE68919361 D1 DE 68919361D1
Authority
DE
Germany
Prior art keywords
treatment
infarts
myocard
therapeutic compositions
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68919361T
Other languages
English (en)
Other versions
DE68919361T2 (de
Inventor
Donogh O'brien
Gordon Vehar
Josiah Wilcox
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE68919361D1 publication Critical patent/DE68919361D1/de
Publication of DE68919361T2 publication Critical patent/DE68919361T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE68919361T 1988-06-21 1989-06-14 Therapeutische zusammensetzungen für die behandlung von myocard-infarkten. Expired - Lifetime DE68919361T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20966588A 1988-06-21 1988-06-21
US23759588A 1988-08-25 1988-08-25
PCT/US1989/002598 WO1989012463A1 (en) 1988-06-21 1989-06-14 Method and therapeutic compositions for the treatment of myocardial infarction

Publications (2)

Publication Number Publication Date
DE68919361D1 true DE68919361D1 (de) 1994-12-15
DE68919361T2 DE68919361T2 (de) 1995-05-24

Family

ID=26904371

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68919361T Expired - Lifetime DE68919361T2 (de) 1988-06-21 1989-06-14 Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.

Country Status (6)

Country Link
EP (1) EP0420937B1 (de)
JP (1) JP2749167B2 (de)
AT (1) ATE113846T1 (de)
CA (1) CA1340633C (de)
DE (1) DE68919361T2 (de)
WO (1) WO1989012463A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5879677A (en) * 1992-12-09 1999-03-09 The Scripps Research Institute Method for inhibition of cerebral tissue factor mediated reperfusion damage
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
AU2003210802B2 (en) 2002-02-05 2009-09-10 Genentech Inc. Protein purification
HUE029951T2 (en) 2003-07-28 2017-04-28 Genentech Inc Reduction of Protein A Dissolution in Protein A Affinity Chromatography
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
AU2008209404B2 (en) 2007-01-22 2012-08-16 Genentech, Inc. Polyelectrolyte precipitation and purification of antibodies
PT3597659T (pt) 2007-07-09 2023-04-04 Genentech Inc Prevenção da redução de ligações de dissulfureto durante a produção recombinante de polipéptidos
US20090148435A1 (en) 2007-10-30 2009-06-11 Genentech, Inc. Antibody purification by cation exchange chromatography
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
ES2527943T5 (es) 2008-08-14 2019-03-07 Genentech Inc Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas
MX2011002372A (es) 2008-09-10 2011-04-04 Genentech Inc Composiciones y metodos para la prevencion de la degradacion oxidativa de proteinas.
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
CN102257122B (zh) 2008-12-16 2015-07-29 Emd密理博公司 搅拌槽反应器及方法
WO2010074702A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Purification of proteins
EP2400992B1 (de) 2009-02-27 2015-07-22 Genentech, Inc. Verfahren und zusammensetzungen zur kennzeichnung von proteinen
IL264336B2 (en) 2009-08-11 2024-02-01 Genentech Inc Production of proteins in cell culture medium without glutamine
SI2473617T1 (sl) 2009-09-01 2020-07-31 F. Hoffmann-La Roche Ag Izboljšano prečiščevanje beljakovin z modificirano elucijo beljakovine A
CN106983862A (zh) 2010-03-22 2017-07-28 弗·哈夫曼-拉罗切有限公司 对于稳定含有蛋白质的制剂有用的组合物和方法
MX2012012743A (es) 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
DK2571903T3 (da) 2010-05-17 2019-11-04 Emd Millipore Corp Polymerer, der reagerer på stimuli, til oprensning af biomolekyler
HUE030820T2 (en) 2010-05-28 2017-06-28 Hoffmann La Roche Decreasing Lactate Levels and Enhancing Polypeptide Production by Control of Lactate Dehydrogenase and Pyruvate Dehydrogenase Kinase Expression
PT2582728T (pt) 2010-06-15 2017-11-23 Genmab As Conjugados fármaco-anticorpo humano contra fator tecidual
BR112012033002B1 (pt) 2010-06-24 2021-10-13 Genentech, Inc Composição aquosa de matéria, método de inibição de agregação induzida por agitação e método de prevenção de oxidação
KR20130100125A (ko) 2010-08-13 2013-09-09 제넨테크, 인크. 질환의 치료를 위한, ＩＬ-1β 및 ＩＬ-18에 대한 항체
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
DK2732021T3 (da) 2011-07-08 2020-07-27 Emd Millipore Corp Forbedrede dybdefiltre til bioteknologiske engangsfremgangsmåder
AU2012355356B2 (en) 2011-12-22 2017-10-12 Genentech, Inc. Ion exchange membrane chromatography
US20140080180A1 (en) 2012-03-27 2014-03-20 Genentech, Inc. Harvest operations for recombinant proteins
NZ725654A (en) 2012-05-18 2018-04-27 Genentech Inc High-concentration monoclonal antibody formulations
CN104994885B (zh) 2012-12-19 2017-09-29 基因泰克公司 用于放射性卤素蛋白质标记的方法和组合物
CN106686977B (zh) 2014-07-09 2022-03-25 豪夫迈·罗氏有限公司 Ph调整以改善细胞库的解冻复苏
RU2757314C2 (ru) 2016-01-22 2021-10-13 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
KR20190012145A (ko) 2016-03-29 2019-02-08 젤터, 인코포레이티드 주변세포질 부피 대 세포질 부피의 비가 0.5:1 내지 10:1인 그람-음성 박테리아에서의 단백질의 발현
JP7022081B2 (ja) 2016-06-14 2022-02-17 メルク・シャープ・アンド・ドーム・コーポレーション 抗凝固因子ｘｉ抗体
MX2019007433A (es) 2016-12-22 2019-08-16 Genentech Inc Metodos y formulaciones para reducir el tiempo de reconstitucion de los polipeptidos liofilizados.
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
RS65472B1 (sr) 2018-07-03 2024-05-31 Bristol Myers Squibb Co Postupak proizvodnje rekombinantnih proteina
EP3864127A1 (de) 2018-10-10 2021-08-18 Boehringer Ingelheim International GmbH Verfahren zur membrangasübertragung in einer hochdichten bioreaktorkultur
AR118536A1 (es) 2019-04-01 2021-10-20 Genentech Inc Composiciones y métodos para estabilizar formulaciones que contienen proteína
TW202104254A (zh) 2019-04-12 2021-02-01 美商格爾托公司 重組彈性蛋白及其生產
US20220315887A1 (en) 2019-08-01 2022-10-06 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
CN116194570A (zh) 2020-09-22 2023-05-30 百时美施贵宝公司 用于产生治疗性蛋白的方法
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US5009888A (en) * 1987-04-13 1991-04-23 Genzyme Corporation Therapeutic enzyme-antibody complexes

Also Published As

Publication number Publication date
ATE113846T1 (de) 1994-11-15
EP0420937A1 (de) 1991-04-10
CA1340633C (en) 1999-07-06
EP0420937B1 (de) 1994-11-09
JP2749167B2 (ja) 1998-05-13
WO1989012463A1 (en) 1989-12-28
DE68919361T2 (de) 1995-05-24
JPH03505329A (ja) 1991-11-21

Similar Documents

Publication Publication Date Title
DE68919361D1 (de) Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
DE3885419D1 (de) Für die direkte Expression von aktiviertem menschlichen Protein-C verwendbare Vektoren und Zusammensetzungen.
MX9606386A (es) Agentes que afectan la hemostasis trombotica.
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
FI840748A (fi) Kinolonkarbonsyror, foerfarande foer deras framstaellning och dessa innehaollande antibakteriella aemnen.
DE3587741D1 (de) Behandlung von Hautkrankheiten.
EP0119161A3 (en) Benzazoquinone and benzazoninone derivatives, process for their preparation, their pharmaceutical preparations as well as their therapeutic use
PT77898B (en) Process for the preparation of substituted 4-amino-methylenochromanes and 4-aminomethylenecromenes acting on the blood circulation and application thereof in the preparation of pharmaceutical compositions acting on the blood circulation
SG48298A1 (en) Saccharin deriatives useful as proteolytic enzymeinhibitors and preparation of
IT9067434A0 (it) Procedimento per migliorare l'efficacia terapeutica di corticosteroidi liposolubili e composizione per l'attuazione di tale procedimento
NO912435D0 (no) Farmasoeytiske preparater.
DK0383417T3 (da) Flagmusespyt-plasminogenaktivator v-PAalfa1
FR2651435B1 (de)
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE120645T1 (de) Verfahren und therapeutische zubereitungen für die behandlung von gerinnungsstörungen.
ZA875847B (en) Pharmaceutical compositions for the treatment of occlusive vascular diseases
IT1227456B (it) Nuovi alcossi derivati di ginkgolidi, loro preparazione e composizioni terapeutiche che li contengono
ES2042529T4 (es) Un procedimiento para preparar una composicion terapeutica combinada de un eliminador de radicales libres o inhibidor metabolico y una proteina biologicamente activa.
SE8402199D0 (sv) Pharmazeutisches preparat enthaltend co-dergocrine und einen calcium-antagonisten
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
RO86562A2 (ro) Compozitie vegetala medicamentoasa pentru tratarea unor afectiuni hepato-biliare
ATE75938T1 (de) Enantiomere des propafenons enthaltende therapeutische mittel.
IT8467183A1 (it) Composizione farmaceutica per la profilassi ed il trattamento dell'arteriosclerosi.
EA199800953A1 (ru) Компонент в, используемый в качестве рубцующего агента, содержащая его фармацевтическая композиция и способ лечения

Legal Events

Date Code Title Description
8364 No opposition during term of opposition